|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 9,029,416: Scope and Claims
Patent 9,029,416, issued on May 12, 2015, to Merck Sharp & Dohme Corp., relates to the use of a crystalline form of a drug compound known as Sitagliptin Phosphate Hydrate. The patent provides protection for specific crystalline forms and methods of manufacturing, with claims centered primarily on crystalline compositions, their preparation, and uses in treating diabetes mellitus.
Scope of Patent Claims
The patent's claims broadly cover:
-
Crystalline Forms: The patent claims crystalline forms of Sitagliptin Phosphate Hydrate, emphasizing specific polymorphic forms characterized by their X-ray powder diffraction (XRPD) and other physicochemical properties.
-
Preparation Methods: Claims include processes to produce the crystalline forms, detailing aspects like solvent systems and crystallization conditions.
-
Pharmaceutical Uses: Method claims cover the administration of these crystalline forms for treating type 2 diabetes mellitus, including dosage regimens.
Key Claims Breakdown
| Claim Type |
Content Summary |
Notable Details |
| Crystalline Forms |
Claims on crystalline Sitagliptin Phosphate Hydrate with specific XRPD patterns and thermal properties |
Includes crystalline polymorphs with distinct diffraction peaks; claims may specify hydrate content, particle size, or stability parameters |
| Production Methods |
Processes involving dissolving Sitagliptin in a solvent, crystallization under controlled conditions, and isolation of specific crystalline forms |
Examples include specific solvent choices like isopropanol, or temperature ranges (e.g., 20-25°C) |
| Therapeutic Methods |
Use of the crystalline forms for preparation of medicaments for managing blood glucose levels |
Claims extend to methods of dosing, formulation considerations, and routes of administration |
Claim Limitations and Patent Coverage
- The claims focus on crystalline hydrate forms with defined XRPD patterns, thereby excluding amorphous or other polymorphic forms.
- The patent covers manufacturing processes that reliably produce these crystalline forms.
- It claims use in treating diabetes, limiting coverage to pharmaceutical applications related to these crystalline forms, but not necessarily their use with other active ingredients or in combination therapies.
Patent Landscape Analysis
Related Patents and Prior Art
- The patent references prior crystalline forms of Sitagliptin phosphate, such as U.S. Patent 8,649,084, which describes amorphous and crystalline formulations.
- The landscape features multiple patents around crystalline forms and synthesis methods for DPP-4 inhibitors (Sitagliptin class), including differentiation through specific hydrate forms, polymorphic variations, and manufacturing techniques.
Patent Families and Continuations
- Merck has filed continuation applications to extend claims coverage, targeting specific crystalline forms with enhanced stability or bioavailability.
- Similar patents exist for other DPP-4 inhibitors with claim overlaps, creating a dense patent thicket.
Geographical Patent Coverage
- The primary patent has counterpart filings in Europe (EP 2,603,823) and Asia, creating an extensive international patent family.
- These patents may have similar claim structures focusing on crystalline forms and manufacturing processes.
Expiration and Patent Life
- Patent 9,029,416 has a standard expiration date of May 12, 2032, assuming no patent term adjustments or extensions.
- This position limits market exclusivity until that date for the specific crystalline forms described.
Implications for Pharmaceutical Development and Commercialization
- The patent claims protect specific crystalline hydrate forms, which can be advantageous over amorphous forms in terms of stability and manufacturing reproducibility.
- Manufacturers aiming to develop generic versions may seek alternatives avoiding patent claims around these specific forms or develop non-infringing crystalline forms.
- The patent's scope influences formulation strategies, emphasizing the need for alternative crystalline polymorphs or different active ingredient forms to circumvent infringement.
Key Takeaways
- U.S. Patent 9,029,416 encompasses specific crystalline hydrate forms of Sitagliptin phosphate, with claims tailored to structures defined by diffraction patterns and physical stability.
- The patent restricts licensees to a set of crystalline forms, methods of production, and therapeutic uses related to diabetes management.
- The patent landscape is dense, with related filings covering alternative crystalline forms, manufacturing methods, and extended claim sequences, creating a complex thicket for potential biosimilar or generic entrants.
- Understanding the specific polymorphic properties claimed is essential for designing non-infringing formulations or developing alternative crystalline forms.
- The patent’s expiry in 2032 maintains a significant barrier to market entry for generic manufacturers relying on these particular crystalline forms.
FAQs
1. Does U.S. Patent 9,029,416 cover all crystalline forms of Sitagliptin phosphate?
No. It specifically claims crystalline hydrate forms characterized by particular XRPD patterns, excluding amorphous and other polymorphic forms.
2. How does this patent impact generic manufacturers?
Generic firms must avoid infringing crystallinity claims and may focus on developing alternative crystalline forms or non-crystalline formulations not covered by the patent.
3. Are there related patents on Sitagliptin crystalline forms?
Yes. Merck and other entities have filed continuation and related patents covering various crystalline polymorphs, stabilizations, and methods, creating a layered patent landscape.
4. What are the main risks for patent infringement?
Developing crystalline forms that match the patented XRPD pattern or using claimed manufacturing processes risk infringement unless designed differently.
5. When does this patent expire, and what does that mean?
Expiration is scheduled for May 12, 2032. After that, the specific crystalline hydrate forms become part of the public domain.
Sources
- U.S. Patent and Trademark Office. Patent 9,029,416.
- Patent family filings and continuations; publicly available patent databases.
- Merck patent documentation and related literature on Sitagliptin polymorphs.
- Prior art references cited within the patent file.
More… ↓
⤷ Start Trial
|
